权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Immunotherapy of lung cancer using biotechnological methods.

使用生物技术方法对肺癌进行免疫治疗。

基本信息

批准号：
01480338
负责人：
KIMURA Hideki
金额：
$ 4.16万
依托单位：
Chiba University
依托单位国家：
日本
项目类别：
Grant-in-Aid for General Scientific Research (B)
财政年份：
1989
资助国家：
日本
起止时间：
1989 至 1991
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-01480338/
关键词：
Lung Cancer Immunotherapy LAK cell IL-2 Adjuvant treatment LAK Cell Adjuvant療法肺癌免疫療法(AIT)集学的治療 OKT3 LAK細胞 IL2 細胞障害テスト

项目摘要

A controlled, randomized study has been conducted to assess the efficacy of adoptive immunotherapy with Interleukin 2(IL2)and lymphokine activated killer cells(LAK cells)combined with chemotherapy or radiotherapy for advanced non-small cell lung cancer(NSCLC)patients. Out of 403 NSCLC patients who received resection of primary tumors from Jan. 1985 to Dec. 1990 in our hospital, a total of 106 patients with relatively curative and non-curative resection, were entered into a randomized controlled trial of postoperative adjuvant immunotherapy. The former group(n=36)was divided into three groups ; a)Chemotherapy(CDDP+VDS)group(n=13), b)Chemoimmunotherapy(CDDP+VDS+IL2+LAK cells)group(n=12), and c)control group(n=ll). The latter(noncurative)group(n=68)was randomized into d)immunotherapy(chemo/radiotherapy+IL2+LAK cells)group(n=33)and e)control(chemo/radiotherapy alone)group(n=35).The overall 4 year survival rates of immunotherapy(b+d)and control(a+c+e)groups were 52.4% and 28.3% respectively and the difference was significant(p<0.01)with generalized Wilcoxon test. In the relative curative group, the 4 year survival rates of a), b), and c)groups were 34.2%, 70.9% and 34.1% respectively. In the non-curative group, those of d)and e)groups were 43.1% and 29.3%(p<0.05). From this study, it it suggested that adoptive immunotherapy with IL2 and LAK cells is effective as a postoperative adjuvant immunotherapy for advanced NSCLC patients.

本研究采用随机对照的方法，观察了白细胞介素2（IL 2）和淋巴因子激活的杀伤细胞（LAK细胞）过继免疫治疗联合化疗或放疗治疗晚期非小细胞肺癌（NSCLC）的疗效。对我院1985年1月~ 1990年12月间403例原发性非小细胞肺癌（NSCLC）患者进行术后辅助免疫治疗的随机对照试验。化疗组（CDDP+VDS）13例，免疫化疗组（CDDP +VDS+ IL 2 +LAK细胞）12例，对照组（n = 11）。免疫治疗组（B+d）和对照组（a+c+e）的4年生存率分别为52.4%和28.3%，经广义Wilcoxon检验，差异有显著性（P<0.01）。相对治愈组中，a）、B）、c）组的4年生存率分别为34.2%、70.9%、34.1%。未治愈组中，d）和e）组分别为43.1%和29.3%（p<0.05）。本研究提示，IL-2和LAK细胞过继免疫治疗是晚期NSCLC患者术后有效的辅助免疫治疗。